Clinical Trials · NCT03710889

Early Effects of Abaloparatide on Tissue-Based Indices of Bone Formation and Resorption

CompletedPhase 3Abaloparatide (Approved)
Phase
Phase 3
Recruitment status
Completed
Sponsor
Radius Health, Inc.
Enrollment
23
Start date
Sep 2018
Locations
4 sites, United States
Primary endpoint
Change From Baseline in Mineralizing Surface/Bone Surface (MS/BS) in the Cancellous Envelope at Month 3
View Abaloparatide compound reference